Zymeworks Inc logo

ZYME - Zymeworks Inc Share Price

$28.49 -1.8  -6.0%

Last Trade - 10/05/21

Mid Cap
Market Cap £1.00bn
Enterprise Value £706.7m
Revenue £22.4m
Position in Universe 2546th / 6854
Unlock ZYME Revenue
Relative Strength (%)
1m -3.22%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -48.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
9.66 11.0 51.8 53.0 29.5 39.0 24.4 115.8 +32.2%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ZymeworksInc revenues decreased 92% to $644K. Net loss increased 43%to $44.6M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Higher net loss reflects Research anddevelopment increase of 21% to $44.3M (expense), Foreignexchange (loss) gain decrease from $3.2M (income) to $63K(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ZYME
Graphical History


ZYME Revenue Unlock ZYME Revenue

Net Income

ZYME Net Income Unlock ZYME Revenue

Normalised EPS

ZYME Normalised EPS Unlock ZYME Revenue

PE Ratio Range

ZYME PE Ratio Range Unlock ZYME Revenue

Dividend Yield Range

ZYME Dividend Yield Range Unlock ZYME Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ZYME EPS Forecasts Unlock ZYME Revenue
Profile Summary

Zymeworks Inc. a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It product candidate ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated May 2, 2017
Public Since April 28, 2017
No. of Shareholders: 28
No. of Employees: 383
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange New York Stock Exchange
Shares in Issue 46,164,888
Free Float (0.0%)
Eligible for
ZYME Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ZYME
Upcoming Events for ZYME
Tuesday 3rd August, 2021 Estimate
Q2 2021 Zymeworks Inc Earnings Release
Monday 1st November, 2021 Estimate
Q3 2021 Zymeworks Inc Earnings Release
Frequently Asked Questions for Zymeworks Inc
What is the Zymeworks Inc share price?

As of 10/05/21, shares in Zymeworks Inc are trading at $28.49, giving the company a market capitalisation of £1.00bn. This share price information is delayed by 15 minutes.

How has the Zymeworks Inc share price performed this year?

Shares in Zymeworks Inc are currently trading at $28.49 and the price has moved by -20.87% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zymeworks Inc price has moved by -44.82% over the past year.

What are the analyst and broker recommendations for Zymeworks Inc?

Of the analysts with advisory recommendations for Zymeworks Inc, there are there are currently 7 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zymeworks Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Zymeworks Inc next release its financial results?

Zymeworks Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Zymeworks Inc dividend yield?

Zymeworks Inc does not currently pay a dividend.

Does Zymeworks Inc pay a dividend?

Zymeworks Inc does not currently pay a dividend.

When does Zymeworks Inc next pay dividends?

Zymeworks Inc does not currently pay a dividend.

How do I buy Zymeworks Inc shares?

To buy shares in Zymeworks Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zymeworks Inc?

Shares in Zymeworks Inc are currently trading at $28.49, giving the company a market capitalisation of £1.00bn.

Where are Zymeworks Inc shares listed? Where are Zymeworks Inc shares listed?

Here are the trading details for Zymeworks Inc:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: ZYME
What kind of share is Zymeworks Inc?

Based on an overall assessment of its quality, value and momentum, Zymeworks Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zymeworks Inc share price forecast 2021?

Shares in Zymeworks Inc are currently priced at $28.49. At that level they are trading at 83.04% discount to the analyst consensus target price of 0.00.

Analysts covering Zymeworks Inc currently have a consensus Earnings Per Share (EPS) forecast of -4.326 for the next financial year.

How can I tell whether the Zymeworks Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zymeworks Inc. Over the past six months, the relative strength of its shares against the market has been -38.38%. At the current price of $28.49, shares in Zymeworks Inc are trading at -23.49% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zymeworks Inc PE Ratio?

We were not able to find PE ratio data for Zymeworks Inc.

Who are the key directors of Zymeworks Inc?

Zymeworks Inc's management team is headed by:

Lota Zoth - CHM
Ali Tehrani - PRE
Neil Klompas - CFO
Anthony Polverino - EVP
Neil Josephson - OTH
Who are the major shareholders of Zymeworks Inc?

Here are the top five shareholders of Zymeworks Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 10.27% (4.74m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 9.32% (4.30m shares)
Fidelity Canadian Growth Company Fund Mutual Fund
Percentage owned: 4.22% (1.95m shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 3.96% (1.83m shares)
Credit Suisse (Lux) Digital Health Equity Fund Mutual Fund
Percentage owned: 3.79% (1.75m shares)
Similar to ZYME
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.